Phototherapy as a Treatment for Uremic Pruritus - A Review

Amrit Thakur1, Soham Chaudhari2, Prakash Chaudhari3 and Magendra Thakur4

1Danbury Hospital, Department of Medical Education & Research, Danbury, CT, USA
2Palisades Medical Center, North Bergen, NJ, USA
3Associated Pathologists Chartered, Las Vegas, NV, USA
4St. Lawrence Pulmonology, Potsdam, NY, USA

Corresponding author: Soham Chaudhari, Palisades Medical Center, 7600 River Road, North Bergen, NJ 07047, USA, Tel: (702) 267-8393; Fax: (702) 361-4747; E-mail: s.chaudhari14@gmail.com

Rec date: July 21, 2015 Acc date: August 18, 2015 Pub date: August 24, 2015

Abstract

Generalized Pruritus (GP) is chronic itch that occurs without any associated diagnosable skin diseases or primary skin lesions. Uremic pruritus (UP), also known as Chronic Kidney Disease-associated pruritus (CKD-aP), is the most common cause of GP and is a debilitating symptom in patients with end-stage renal disease. Topical therapy is often inadequate; thus, providing additional therapeutic options becomes essential for the successful primary care physician. Phototherapy is a proven method for the management of many pruritic disorders, including uremic pruritus (UP).

Objective: This review aims to give an update on the use of phototherapy for managing UP to establish it within the spectrum of therapeutic options. The pathogenesis of UP and the mechanism of action of phototherapy in treating UP were also reviewed.

Methods: A thorough literature search of the PubMed database was conducted to identify studies that examined a variety of phototherapy methods in UP.

Results: UP causes a microinflammatory state with changes in cutaneous nociceptive endings. A circulating substance responsible for pruritus is annihilated through the apoptotic actions of phototherapy. BB-UVB is the preferred modality to decrease UP.

Conclusion: Phototherapy is a safe and beneficial option when other measures fail to control UP.

Keywords: Phototherapy; Pruritus; Uremic pruritus; Chronic Kidney Disease-associated pruritus

Introduction

GP is chronic itch that occurs without any associated diagnosable skin diseases or primary skin lesions. Although frequently idiopathic, it can be secondary to neurologic disorders, chronic renal failure, cholestasis, systemic infections, malignancies, and endocrine disorders. A judicious history, thorough physical examination, and suitable laboratory investigation must be performed to elucidate the cause. Systemic disease has been implicated in up to 20% of patients with GP [1]. Special emphasis should be placed on drug exposure, travel history, environmental irritants, lifestyle, extra-cutaneous symptoms, and prior hospitalizations. Initial laboratory tests may include complete blood count, liver and renal function tests, serum glucose, iron, ferritin, thyroid function tests, erythrocyte sedimentation rate, protein electrophoresis, and urinalysis. Many cases of GP begin in a localized area, and phototherapy can often lead to cessation of generalized itch and reveal a previously localized itch. Generalization can be caused by a lowering of itch threshold on other body parts through a combination of neurologic and/or psychological mechanisms.

Those with a negative workup for GP fall into idiopathic pruritus (IP). In those over the age of 65, this form of idiopathic itch is often dubbed senile pruritus or Willan’s itch as it is often associated with dry skin [2]. The stratum corneum thickens with age and has decreased kertohyaline granules. Elderly patients with dry skin have decreased amount of surface lipids which impair the stratum corneum’s ability to hold water [3]. Clearance of debris from the dermis also decreases, along with sweat and sebum production and vascular response to histamine. Xerosis was found to be proportional to the degree of itch with increased intracorneal cohesion and no difference in response to intradermal histamine [4].

End-stage renal disease (ESRD) is defined as progressive and irreversible kidney dysfunction that lasts longer than 3 months [5]. An estimated 50-100% of patients with ESRD have at least one associated cutaneous change [6,7]. These include pigmentary disorders, pruritus, xerosis, acquired ichthyosis, half-and-half nail, acquired perforating dermatosis, calciphylaxis, bullous dermatoses, and fibrosing dermopathy of uremia [5]. Uremic pruritus (UP), also known as Chronic Kidney Disease-associated pruritus (CKD-aP), is a debilitating symptom in patients with ESRD. Of all the systemic disorders linked to pruritus, uremia is the most common [8]. Its prevalence varies from 15% to 90% and has been found as the most common symptom experienced by patients on hemodialysis when...
compared to other cutaneous manifestations [9-11], 15-49% of those with chronic renal failure (CRF) and 90% receiving dialysis have uremic pruritus (UP) [12]. Up to 50% of UP patients complain about generalized pruritus [8,13]. In the remaining, UP affects predominantly back, face, and shunt-arm [10]. Nearly half of hemodialysis patients experience continued pruritus, whereas for others, it occurs occasionally with episodes of exacerbation [14]. Clinically, UP skin resembles that of hemodialysis patients without pruritus, dry and scaly. No primary skin lesions are seen; however, chronic excoriations, linear crusts, and ulcerations can evolve. Pruritus of hemodialysis and that of peritoneal dialysis occur in similar a frequency [15,16]. Although the incidence of pruritus increases as renal function deteriorates, it does not improve with dialysis and is an independent marker of mortality at 3 years for those on hemodialysis. [17]. The severity of UP is associated with the duration of dialysis and xerosis. Unfortunately, the prevalence and burden of pruritus in end-stage renal disease (ESRD) is often underestimated by nephrologists [18], even though it is perceived by patients as a severe and distressing symptom of renal failure [19]. With symptoms lasting for months to years, its chronic nature is an independent predictor of poor quality of life with severe sleep disturbances [16,20,21]. It is postulated that periods of inactivity at night and during dialysis sessions exacerbates pruritus [10,22]. UP is a major cause of distress to patients and has a significant impact on quality of life. Common treatments for UP include antihistamines, steroids, emollients, and charcoal [23]. However, Topical therapy is often inadequate in controlling pruritus. Therefore, providing additional therapeutic options becomes essential. While there have been some reports of effective treatment with serotonin antagonists, selective serotonin reuptake inhibitors, mast cell stabilizers, leukotriene receptor antagonists, nicotinamide, and opioid receptor antagonists, the side effects of these medications cannot be easily overlooked [24].

Phototherapy is a safe and efficacious management modality which decreases pruritus and can be used across age groups [25]. Ultraviolet-based therapy (phototherapy and photochemotherapy) [26] can provide relief for UP patients without many of the risks and adverse effects of systemic medications. UVB (290-320 nm) and UVA (320-400 nm) are implemented in UV-based therapy. Broadband UVB (BB-UVB) and broadband UVB (BB-UVA) use a light source covering their entire spectrum. Narrowband UVB (NB-UVB) uses 311-313 nm and UVA1 uses 340-400 nm with a peak at 365 nm. UVA1 can be administered at high dose (HD-UVA1) (130 J/cm²), medium dose (MD-UVA1) (50 J/cm²), and low dose (LD-UVA1) (20 J/cm²). Monochromatic Excimer Laser (MEL) (308 nm) is a more targeted phototherapy device which delivers 308 nm UVB to a localized area and can expand treatment options by sparing unaffected areas. This review article focuses on the efficacy of these forms of phototherapy to treat UP.

Methods

For this systematic review we concentrated on the therapeutic role of phototherapy for UP. The computerized bibliographic database PubMed was used to conduct a search for English articles from inception to August of 2014. Research articles of randomized controlled trials (RCT), open prospective studies, pilot studies, and retrospective observations on NB-UVB, BB-UVB, UVA, PUVA, and MEL were included. The following key words were used: “phototherapy pruritus, and phototherapy uremic pruritus.” Based on the keywords chosen, 178 articles were revealed. After screening title and abstract, those studies in which phototherapy was not used as a treatment for the chosen disease processes were excluded. Reference lists in review articles were also searched. Abstracts only and duplicates were excluded. This left 58 articles for the screening phase. These records were then assessed for eligibility, excluding other modes of treatment as primary analysis, thereby leaving 12 studies in the final analysis. Relevant data including study design, number of participants, duration of treatment, cumulative phototherapy dosing, adverse effects, and clinical outcome were retrieved from the articles and formulated into spreadsheet databases. When specific pruritus assessment scales were mentioned, we cited them in the results. If no particular assessment scale was used, extent of disease, sleep improvement, and remission were evaluated. Because pruritus is the main symptom of these disorders, the above criteria may be considered synonymous to the resolution of pruritus.

Results

NB-UVB

Forty-nine percent of the UP patients treated with NB-UVB resulted in moderate to significant improvement [27]. A study conducted by Seckin compared UP to IP [28]. 68% of those with IP showed greater than 50% improvement with a 61% remission rate on a 6 month average follow-up. 60% in the UP group showed greater than 50% improvement with 66.7% recurrence on follow-up. Although remission after a single course of NB-UVB therapy is not prolonged, 54.2% in the UP group and 67.9% in the IP group had a change in visual analog score (VAS). Thus, NB-UVB can be considered as a valuable alternative treatment, even though long term cure is not possible. An open pilot study evaluated pruritus using the VAS and a detailed cumulative score (DCS) and found 70.8% decrease on the VAS scale and a 71.8% decrease on the DCS [29,30]. 43% were in remission 6 months after completing treatment, with 57% having a recurrence of pruritus on average within 2.5 months. A more recent single-blinded study noted comparable and significant reduction of pruritus intensity in patients treated with both NB-UVB and control during the course of phototherapy and follow-up [26,31]. While the NB-UVB group showed a significant improvement in the involved body surface area affected by pruritus (p=0.006) and had lower pruritus intensity scores at certain time points, the beneficial effects were marginal comparatively.

BB-UVB

BB-UVB phototherapy was first described to be useful for achieving a reduction in UP in the late 70’s [32]. Ninety percent of patients in the BB-UVB arm responded and 80% remained free of pruritus on an average of 7 months follow-up. The UVA arm did not experience an improvement in itch intensity and was considered placebo, as proven initially by Taylor et al., an additional study done comparing BB-UVB to placebo found BB-UVB beneficial in decreasing pruritus [33]. One crossover study found BB-UVB and UVA to be equal to placebo, however this study did not have an intervening washout period and therefore the placebo rate can be enhanced, consequently diminishing the therapeutic significance of BB-UVB [34]. Berne et al reported a decrease in epidermal vitamin A content in a study with 10 UP patients treated with whole-body UVA and BB-UVB [35]. Epidermal retinal concentrations were returned to normal after 12 sessions of phototherapy, and 70% reported relief from pruritus [36].
A study comparing half-body BB-UVB to whole-body treatments with varying dosimetry, found a reduction in pruritus in eighty-four percent of patients treated with whole-body BB-UVB, with 29% not relapsing on an average of 10 month follow up [37]. Because patients did not detect a difference in the degree of pruritus between the half-body BB-UVB and placebo side, BB-UVB phototherapy was concluded to exert a systemic effect on UP secondary to the generalized response. The more intensive schedules accelerated the response temporarily, but it did not increase the percentage of patients who responded. In addition, the beneficial effects of UV exposure were only experienced after a lag time of 2 weeks in some patients. In another study, 80% of patients responded with complete relief of itching when treated with BB-UVB [38]. Twenty-five-percentage of these claimed relief everywhere except for the palms and soles. All patients in this study had relief at least one month after therapy was discontinued with 60% maintaining relief for at least six months. Cohen et al reported that 57% of a series of pruritic patients experienced relief after BB-UVB therapy with a decrease in dermal mast-cell counts accompanying improvement in VAS scores [39]. Finally, a case report by Hsu et al has found BB-UVB more effective in decreasing pruritus in UP than NB-UVB (Table 1) [40].

<table>
<thead>
<tr>
<th>Reference, type of study</th>
<th>Participants (n)</th>
<th>Treatment Regimen</th>
<th>Cumulative Dose (J/cm²)</th>
<th>Pruritus Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samson Yashar RCS [27]</td>
<td>6</td>
<td>33 irradiations</td>
<td>NB-UVB: 52</td>
<td>33% had significant improvement (66-100% resolution of lesions and/or reduction of pruritus intensity)</td>
</tr>
<tr>
<td>Seckin [28] RCT</td>
<td>UP-22 IP-22</td>
<td>3x/wk for 22 irr</td>
<td>NB-UVB for UP: 24.54</td>
<td>UP: 60% had &gt;50% improvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB for IP: 20.801</td>
<td>IP: 68% had &gt;50% improvement</td>
</tr>
<tr>
<td>Ada [29] RCT</td>
<td>10</td>
<td>3x/wk for 6 wks</td>
<td>NB-UVB: NR</td>
<td>70.8% decrease with 43% in remission after 6 months</td>
</tr>
<tr>
<td>Ko [31] RCT</td>
<td>21</td>
<td>3x/wk for 6 wks</td>
<td>NB-UVB: NR UVA: 1-6</td>
<td>NB-UVB=UVA</td>
</tr>
<tr>
<td>Gilchrest [32] RCT</td>
<td>18</td>
<td>2x/wk for 4 wks</td>
<td>BB-UVB: NR UVA (placebo): NR</td>
<td>90% had decreased pruritus</td>
</tr>
<tr>
<td></td>
<td>BB-UVB and UVA: 2x/wk for 4 wks</td>
<td>BB-UVB: NR</td>
<td>BB-UVB: 38 75% responded</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whole body BB-UVB: NR</td>
<td>UVA: NR</td>
<td>66% responded</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BB-UVB: NR</td>
<td>UVA: NR</td>
<td>83% responded</td>
</tr>
<tr>
<td>Blachley [34] RCS</td>
<td>BB-UVB: 9 UVA:8</td>
<td>3x/wk for 2 wks</td>
<td>BB-UVB: NR UVA: NR</td>
<td>BB-UVB &gt; UVA</td>
</tr>
<tr>
<td>Berne [36] RCT</td>
<td>10</td>
<td>12 irradiations</td>
<td>BB-UVB: 7.9 UVA: 1.3</td>
<td>70% had relief</td>
</tr>
<tr>
<td>Schultz [38] RCT</td>
<td>10</td>
<td>2-3x/wk</td>
<td>BB-UVB: NR</td>
<td>80% had complete relief</td>
</tr>
<tr>
<td>Cohen [39] RCT</td>
<td>14</td>
<td>NR</td>
<td>BB-UVB: NR</td>
<td>57% had objective benefit, 100% had decreased itch intensity</td>
</tr>
<tr>
<td>Hsu [40] CR</td>
<td>1</td>
<td>BB-UVB: a)First Course: 8 irradiations b) Second Course: 10 irradiations c) Third Course: 10 irradiations</td>
<td>First course: 0.12 Second Course: 0.23 Third Course: 0.76 NB-UVB: 2</td>
<td>BB-UVB &gt; NB-UVB Cumulative dose of BB-UVB for a good response increases with repeated treatment</td>
</tr>
</tbody>
</table>

Table 1: Phototherapy for treatment of uremic pruritus.
Discussion

Bernhard classified itch into dermatologic, systemic, neurogenic, psychogenic, mixed, and other categories [41]. While this can help determine the etiology to address management options, the inability to quantify pruritus remains a significant barrier to evolving understanding. Because objective measurements of pruritus are lacking, it is difficult to adequately assess and compare treatments until a uniform, consistent, and reliable scale of evaluating pruritus and scratching exists. Nonetheless, based on current methodologies which involve subjective evaluations, we have attempted to compare the different forms of phototherapy in treating pruritus.

Pathogenesis of itch

Localized itch involves alpha-delta fibers whereas diffuse, generalized itch is transmitted through dermal unmyelinated c-fibers. Both of these nociceptive fibers travel to the dorsal horn of the spinal cord which is then processed by the cerebral cortex through the spinothalmic tract [42]. They have a slow conduction velocity and innervate large areas of the skin [43]. Dry skin and disruption of the skin barrier can induce keratinocytes to release pruritogenic substances [44]. Nerve fibers typically end at the dermal-epidermal junction, although some project into the epidermis [45]. Itch receptors, formed mostly by keratinocytes, respond to pruritogens, such as histamine, proteases, growth factors, neuropeptides, cytokines, and opioids [46-47] (Figure 1). They are found only in skin, mucus membranes, and cornea [48]. Substance P (SubP) and calcitonin gene-related peptide (CGRP) are the most studied neurotransmitters and have both central and peripheral activity [49,50]. Allokinesis, the experience in response to sweat or sudden changes in ambient temperature, does not change the quality of itch into pain. Histamine-induced itch is observed in patients with UP [51]. While pain causes one to avoid a motor response, itch causes a stimulatory motor response. Painful stimuli can inhibit itch as observed in pruritic patients who only stop scratching once skin lesions begin bleeding and become painful. Itch and pain share the same cortical brain areas, but have different patterns of activation; itch has a weaker activation of somatosensory cortices with a stronger activation of ipsilateral motor areas as compared with pain processing [54,55].

Pathogenesis of UP and mechanism of action for phototherapy in UP

The term “uremic pruritus” is not apt because UP does not result from an increase in serum urea levels. Although the pathogenesis of UP is not completely understood, it is known to present with dystrophic neurotrophic changes in cutaneous nociceptor nerve endings, with a “microinflammatory” state of increased Th1 markers, chemokines, and Interleukin (IL)-6 [56,57]. Several studies have shown an increase in skin concentrations of calcium, magnesium, aluminum, and phosphorus in hemodialysis patients with pruritus, compared to hemodialysis patients with pruritus and controls [8,14,34,58-60]. An increase in the concentration of these molecules causes microprecipitation in the skin leading to pruritus. Few studies show a correlation between serum levels of these ions and pruritus [61-63]. UP also causes hyperparathyroidism, anemia, increased serum histamine levels, and peripheral neuropathy [12,64]. Parathyroid hormone increases serum levels of histamine and mast cell proliferation and dramatic improvement in pruritus has been noted after parathyroidectomy [65-67]. However, upon intradermal application of parathormone, no cutaneous reaction or skin biopsy changes was detected [68]. Neither serum phosphate nor other tests of bone and mineral status were determined to be significant predictors of pruritus at any point in time or over time [69]. Atrophy of sebaceous glands is associated with a decreased lipid film surface and is found in ESRD patients; this leads to dehydration of the stratum corneum and promotes pruritus [70-72]. Reduced hydration of the stratum corneum is higher in patients with UP than those without [14].

UVB therapy is beneficial for patients with UP. Possible mechanisms include reduction in skin divalent-ion content, reduction in Vitamin A and retinol content, stabilization of or reduction in number of mast cells, detoxification of undetermined pruritogenic substances, photoactivation of antipruritogenic substances, and changes in the excitability of epidermal nerve endings. Mast cell proliferation, degranulation, and subsequent histamine release plays a role in uremic pruritus [14] (Figure 2). Histamine secretion is evoked by an increased release of SubP. NB-UVB induces apoptosis of dermal mast cells and reduces the release of neuropeptides such as SubP by decreasing epidermal nerve fibers [73-75]. Nitric oxide and IL-2 have also been implicated in the pathogenesis of uremic pruritus, both of which are decreased by NB-UVB [73,76-78]. Schulzt et al suggest the response to UVB indicates a deposition of some substance in the skin which is degraded or inactivated by the light. Because uremic patients respond to cholestramine and phototherapy serves to clear bilirubin in jaundiced premature infants, bile salts were considered to be involved in UP pathogenesis. Individuals with advanced CRF had higher levels of serum total bile acids when compared to controls, and those with pruritus had higher levels of bile acids than those without pruritus [79]. Thus, the intensity of pruritus correlated with bile acid concentration [80]. Certain bile acids also cause cytotoxicity to mastocytes, thereby releasing histamine [81].

Figure 1: Pruritus.
Phototherapy is a safe form of treatment. When given long-term, PUVA has been associated with increased risk of cutaneous squamous cell carcinoma, but even high-dose exposure does not increase basal cell carcinoma risk [84]. BB-UVB is considered to be the treatment of choice by some [14]. While UVB radiation is safe, the risk for skin malignancies and long-term immunosuppression remains controversial in immunocompromised patients due to renal transplant. We did not find any studies on the use of PUVA in UP. Thus, more randomized placebo controlled trials are needed in determining the safest and most efficacious form of phototherapy for decreasing pruritus for patients on dialysis.

Safety of phototherapy

Phototherapy is a beneficial, efficacious, efficient, and safe method of treatment for UP. BB-UVB is the most efficacious for UP, while UVA is equal to placebo. Phototherapy decreases UP for skin malignancies and long-term immunosuppression remains controversial in immunocompromised patients due to renal transplant. We did not find any studies on the use of PUVA in UP. Thus, more randomized placebo controlled trials are needed in determining the safest and most efficacious form of phototherapy for decreasing pruritus for patients on dialysis.

Efficacy of phototherapy in UP

Even though NB-UVB is beneficial in decreasing GP & UP, is less erythemogenic, has a lower pruritogenic potential, and is less carcinogenic than BB-UVB, BB-UVB is the treatment of choice for UP, while UVA is equal to placebo [82,83]. In patients who are not candidates for kidney transplant, BB-UVB is considered to be the treatment of choice by some [14]. While UVB radiation is safe, the risk for skin malignancies and long-term immunosuppression remains controversial in immunocompromised patients due to renal transplant. We did not find any studies on the use of PUVA in UP. Thus, more randomized placebo controlled trials are needed in determining the safest and most efficacious form of phototherapy for decreasing pruritus for patients on dialysis.

Limitations

The conclusions that one can draw by systematically analyzing the current medical literature regarding the use of phototherapy in pruritic disorders are limited due to several factors. Publication bias must be considered in any review article, as trials leading to positive results are more likely to be published [91]. Poor statistical power results from small sample size must also be taken into account. Uncommon adverse effects are often not disclosed or perhaps unrecognized. The variability in parameters of each of the different trials must also be taken into account. Different methods for selecting patients, dosing UV radiation, and assessing the response limit the ability to draw detailed conclusions through a comprehensive review of available studies. Despite these drawbacks, the authors found overwhelming evidence after reviewing the data to conclude that phototherapy is helpful for most types of pruritus.

Conclusion

We conclude that phototherapy is a beneficial, efficacious, efficient, and safe method of treatment for UP. BB-UVB is the most efficacious for UP, while UVA is equal to placebo. Phototherapy decreases UP through its apoptotic and anti-inflammatory actions and is therefore a useful therapeutic modality. These data conclude there is sufficient evidence to support the use of UV-based treatment for reducing pruritus and its associated manifestations.

References


